Cargando…

Molnupiravir: A new candidate for COVID‐19 treatment

The novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID‐19. Antiviral medications are the candidate therapies for the management of COVID‐19. Molnup...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pourkarim, Fariba, Pourtaghi‐Anvarian, Samira, Rezaee, Haleh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929331/ https://www.ncbi.nlm.nih.gov/pubmed/34968008 http://dx.doi.org/10.1002/prp2.909

Ejemplares similares

Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview
por: Rezaee, Haleh, et al.
Publicado: (2021)

Molnupiravir for COVID-19
Publicado: (2022)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022)

Review on molnupiravir as a promising oral drug for the treatment of COVID-19
por: Zarenezhad, Elham, et al.
Publicado: (2022)

Molnupiravir in COVID-19: A systematic review of literature
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
por: Yip, Ashley Jia Wen, et al.
Publicado: (2022)

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
por: Jayk Bernal, Angélica, et al.
Publicado: (2021)

Current evidence on the use of anakinra in COVID-19
por: Khani, Elnaz, et al.
Publicado: (2022)

What will be the role of molnupiravir in the treatment of COVID-19 infection?
por: Vitiello, Antonio, et al.
Publicado: (2021)

New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
por: Atmar, Robert L., et al.
Publicado: (2022)

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19
por: Imran, Mohd., et al.
Publicado: (2021)

RdRp inhibitors and COVID-19: Is molnupiravir a good option?
por: Hashemian, Seyed Mohammad Reza, et al.
Publicado: (2022)

The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19
por: Cheng, Shih-Lung, et al.
Publicado: (2023)

Molnupiravir as an Early Treatment for COVID-19: A Real Life Study
por: Pontolillo, Michela, et al.
Publicado: (2022)

Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review
por: Mali, Kalpana Ramanna, et al.
Publicado: (2022)

Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
por: Rasmussen, Henrik Berg, et al.
Publicado: (2023)

Efficacy and safety of molnupiravir for COVID-19 patients
por: Fatima, Maurish, et al.
Publicado: (2022)

Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences
por: Singla, Shivali, et al.
Publicado: (2022)

Characterization of Novel Fragment Antibodies Against TNF-alpha Isolated Using Phage Display Technique
por: Alizadeha, Ali Akbar, et al.
Publicado: (2019)

The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review
por: Kamal, Lina, et al.
Publicado: (2022)

(349) Molnupiravir vs Remdesivir for Treatment of Covid-19 in Lung Transplant Recipients
por: Razia, D., et al.
Publicado: (2023)

Molnupiravir and Its Antiviral Activity Against COVID-19
por: Tian, Lili, et al.
Publicado: (2022)

Vascularite rétinienne post-Covid-19 et Molnupiravir
por: Lassouli, I., et al.
Publicado: (2022)

PANORAMIC: important insights into molnupiravir use in COVID-19
por: Kidd, Michael R, et al.
Publicado: (2023)

Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic
por: Khiali, Sajad, et al.
Publicado: (2022)

Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Tian, Fangyuan, et al.
Publicado: (2023)

Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis
por: Chang, Yi-Chin, et al.
Publicado: (2023)

Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022)

Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
por: Karniadakis, Ioannis, et al.
Publicado: (2023)

Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
por: Kauer, Victoria, et al.
Publicado: (2023)

An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19()
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis
por: Benaicha, Karima, et al.
Publicado: (2023)

NZ's Pharmac negotiates deal for molnupiravir to treat COVID-19
Publicado: (2021)

Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India
por: Sinha, Shubhadeep, et al.
Publicado: (2022)

The effect of molnupiravir on post-acute outcome of COVID-19 survivors
por: Hsu, Wan-Hsuan, et al.
Publicado: (2023)

Nirmatrelvir and Molnupiravir and Post–COVID-19 Condition in Older Patients
por: Fung, Kin Wah, et al.
Publicado: (2023)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data
por: Santi Laurini, Greta, et al.
Publicado: (2022)

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
por: Wen, Wen, et al.
Publicado: (2022)

Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials
por: Gao, Ya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t6ob29i74temfa6akjk0lfh2om